Allogene Therapeutics, Inc.
(NASDAQ : ALLO)

( )
ALLO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.90%168.391.3%$496.78m
BIIBBiogen Inc.
0.65%230.761.3%$480.84m
CELGCelgene Corporation
-0.62%94.831.3%$471.13m
GILDGilead Sciences, Inc.
-0.75%65.860.9%$453.88m
ILMNIllumina, Inc.
-2.29%300.593.5%$305.96m
REGNRegeneron Pharmaceuticals, Inc.
-0.78%302.572.6%$276.84m
AAgilent Technologies, Inc.
-0.29%68.911.6%$198.64m
VRTXVertex Pharmaceuticals Incorporated
-1.78%165.731.9%$176.80m
EXASExact Sciences Corporation
-0.16%96.0425.3%$171.72m
ALXNAlexion Pharmaceuticals, Inc.
-2.80%127.232.0%$150.06m
BMRNBioMarin Pharmaceutical Inc.
-2.31%86.664.3%$118.53m
SRPTSarepta Therapeutics, Inc.
-3.37%117.5714.7%$114.20m
INCYIncyte Corporation
-0.48%76.832.5%$105.26m
IONSIonis Pharmaceuticals, Inc.
0.09%67.468.2%$98.12m
ALNYAlnylam Pharmaceuticals, Inc
-2.49%65.869.2%$93.34m

Company Profile

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam on November 2017 and is headquartered in South San Francisco, CA.